MedTrace Logo

Brilinta Taiwan Post Approval Safety Study

NCT02406248 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2018-10-15

Study results available
· View outcomes & findings →

Summary

A multicenter, single arm, open label, Phase IV study to evaluate safety and to describe the cumulative incidence of major cardiovascular events of Ticagrelor in Taiwanese patients with non ST-segment (a segment in the eletrocardiogram which presents the period when ventricles are depolarized) elevation myocardial infarction

Conditions

  • Non ST-elevation Myocardial Infarction

Interventions

DRUG

Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)

Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)

Sponsors & Collaborators

Principal Investigators

  • Chun-peng Liu, Ph.D · Kaohsiung Veterans General Hospital.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-23
Primary Completion
2017-02-09
Completion
2017-02-09

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02406248 on ClinicalTrials.gov